Gothamist
A non-profit newsroom, powered by WNYC.
Gothamist
Listen Live
News
Johnson & Johnson And Novavax Vaccines May Not Sustain Herd Immunity Against Coronavirus Variants, New Trial Results Reveal
By
Nsikan Akpan
Published Jan 29, 2021
Share
FacebookTwitterRedditEmail
Never miss a story
Email address
By submitting your information, you're agreeing to receive communications from New York Public Radio in accordance with our Terms .
By
Nsikan Akpan
Published Jan 29, 2021
Share
FacebookTwitterRedditEmail
We rely on your support to make local news available to all
Make your contribution now and help Gothamist thrive in 2026. Donate today
Gothamist is funded by sponsors and member donations
Get the COVID-19 vaccines while they still work. New findings from Novavax and Johnson & Johnson and Novavax—two companies with candidates in late-stage clinical trials—show strong protection against the original strain of the coronavirus. But these drugs may not be able to maintain herd immunity and protect communities in the long run.
Early estimates suggested COVID-19 vaccines need to be about 75% effective against infection to establish herd immunity, but Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases said in December that the mark might be closer to 90%. Overall effectiveness for both vaccine candidates fell well below this level when facing the coronavirus variant from South Africa named B.1.351.
“By our PCR [testing], it appears over 90% of the cases [in South Africa] were attributable to the escape variant, and that was, of course, aligning with what we saw in the epidemiology,” Dr. Gregory M. Glenn, President of Research and Development at Novavax, said during a conference call on Thursday. He also added that prior infection with the original strain might not generate immunity to the South African variant, parallelling results from recent studies.
Listen to Nsikan Akpan discuss the vaccines on Morning Edition:
The Maryland-based Novavax presented phase 3 results from South Africa and the U.K, where a different variant is spreading rapidly and overwhelming hospitals. The company’s two-dose vaccine mounted an excellent defense against the original strain of the coronavirus and the U.K. variant, shielding 90% of British takers from mild, moderate, or severe disease.
“With today’s results from our U.K. Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants,” Stanley C. Erck, Novavax President and CEO said in a statement. “In addition, our PREVENT-19 US and Mexico clinical trial has randomized over 16,000 participants toward our enrollment goal of 30,000.”
But in South Africa, the efficacy dropped to 60% due to the rapid spread of the B.1.351 variant, which vibes with earlier reporting that this mutant is more likely to escape our immunity. The protection shrank by another 10% when they included HIV patients, who tend to be immunocompromised.
In response to the Novavax disclosure, Natalie Dean, an epidemiologist at the University of Florida, tweeted enthusiasm over the U.K. trial, but said: "we cannot assume that vaccines are equally effective against all variants."
The long-awaited results from Johnson & Johnson arrived Friday morning. Mayor Bill de Blasio and Governor Andrew Cuomo have recently voiced excitement over this candidate, given it requires only one shot. It can reach more people with fewer doses than the authorized options from Pfizer-BioNTech and Moderna.
Their interim analysis reported 72% efficacy in the U.S., but the overall protection against moderate and severe COVID-19 dropped to 66% when they included results from other countries. Why? Because researchers saw 66% efficacy in Latin America and 57% in South Africa.
On a positive note, the Johnson & Johnson candidate guarded more than four out of five people from severe COVID-19. No deaths or hospitalization were reported among those immunized. Their trial involved 43,783 global participants split across placebo takers and vaccine recipients. The Johnson & Johnson vaccine is produced by its subsidiary Janssen.
Assuming these vaccines block the coronavirus's spread at a similar rate as they stop its disease, these updates bode poorly on their abilities to establish herd immunity. Meanwhile, reaching herd immunity by the summer or autumn was already looking like an uphill battle given the slow nature of the vaccine rollout.
The mutant strains, especially the concerning ones from South Africa and Brazil, place extra urgency on getting doses into people’s arms before the virus spread broadly or make our life-saving drugs ineffective. New Jersey reported the first U.S. death connected to the UK variant, while South Carolina health officials recorded the country’s first cases of the South African variant on Thursday.
Glenn said Novavax is already preparing to update its vaccine formula in a bid to stop the new mutants. Both Pfizer and Moderna are doing the same. Johnson & Johnson launched a second trial in December that added a booster shot to their regimen to increase their overall efficacy.
Gothamist has contacted Johnson & Johnson and Novavax for comment.
Tagged
COVID-19
Johnson & Johnson
coronavirus
padavan
vaccine
Nsikan Akpan
Nsikan is the former editor of the health and science desk at WNYC/Gothamist. Nsikan was previously at National Geographic where he worked as a science editor, overseeing its COVID-19 coverage in addition to other topics in science, health and technology. Before National Geographic, he worked for more than four years at PBS NewsHour, where he co-created an award-winning video series named ScienceScope. He shared a 2020 Emmy for the PBS NewsHour series “Stopping a Killer Pandemic” and in 2019 received a George Foster Peabody Award for the PBS NewsHour series “The Plastic Problem.” Nsikan has also worked for NPR, Science News Magazine, Science Magazine, KUSP Central Coast Public Radio, the Santa Cruz Sentinel and as a writer at the Center for Infection and Immunity at Columbia University. He holds a doctorate in pathobiology from Columbia University and is an alum of the science communication program at the University of California, Santa Cruz.
Read more
Gothamist is funded by sponsors and member donations
Gothamist is funded by sponsors and member donations
MORE news
Councilmembers make new push to improve diversity at NYC specialized high schools
The councilmembers argue the reforms could be implemented immediately.
By
Jessica Gould
Published Sep 13, 2026 at 7:00 a.m. ET
A new queer film festival is coming to Fire Island this month
The inaugural Grove & Pines Film Festival is a three-day event that will take over Cherry Grove and the Pines starting Sept. 18.
By
Giulia Heyward
News
A new queer film festival is coming to Fire Island this month
The inaugural Grove & Pines Film Festival is a three-day event that will take over Cherry Grove and the Pines starting Sept. 18.
By
Giulia Heyward
NYPD lieutenant claims overtime pay was awarded on racial lines in new suit
By
Ben Feuerherd
Flood watch for NYC and NJ: Expect a soggy Saturday night, Sunday morning
By
Louis C. Hochman
'Closer to extinction': NY fights Trump on changes to Endangered Species Act
By
Rosemary Misdary
Never miss a story
Catch up on the most important headlines with a roundup of essential NYC stories, delivered to your inbox daily.
Sign upEmail address
By submitting your information, you're agreeing to receive communications from New York Public Radio in accordance with our Terms .